Last update 15 Sep 2025

COVID-19 Vaccine(Janssen)

Overview

Basic Info

Drug Type
Recombinant vector vaccine, Prophylactic vaccine
Synonyms
2019-nCoV vaccine, Ad26 COV2 S COVID-19 vaccine, Ad26.COV2-S
+ [18]
Action
inhibitors
Mechanism
SARS-CoV-2 S protein inhibitors(SARS-CoV-2 S protein inhibitors)
Active Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (27 Feb 2021),
RegulationEmergency Use Authorization (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19
United States
27 Feb 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Influenza, HumanPhase 3
United States
02 Nov 2021
Influenza, HumanPhase 3
Belgium
02 Nov 2021
Influenza, HumanPhase 3
Poland
02 Nov 2021
Severe Acute Respiratory SyndromePhase 3
South Africa
17 Feb 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
367
myxcoxdwfo(gctvykfewl) = mxpnmaagwm ipvawpamra (xazkcfbkel, 635.3 - 1014.3)
Non-inferior
22 Jul 2025
myxcoxdwfo(gctvykfewl) = bpyxywvvav ipvawpamra (xazkcfbkel, 150.8 - 272.1)
Phase 2
51
messenger Ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccine+COVID-19 mRNA vaccine
(Group 1 (Adults): Ad26.COV2.S 5*10^10 vp)
bfjuzzlxlf = elngfavmod ozwbwxutqm (ktgagjkxry, yegbvaqlpi - fkvgrbvppp)
-
13 Nov 2024
(Groups 2 and 3 (Adults): Ad26.COV2.S 5*10^10 vp)
bfjuzzlxlf = drgmcggbcb ozwbwxutqm (ktgagjkxry, zjvwpkijkt - myopgjzwkd)
Phase 3
31,835
adenovirus type 26 vector coronavirus-2 spike protein (Ad26.COV2.S)
(Double Blind Phase: Ad26.COV2.S)
urpwluglbo = qfctdrthin efpipkdysz (qvutvjlonn, pzaxcavvek - oqyxsrwatn)
-
09 Oct 2024
placebo+Ad26.COV2.S
(Double Blind Phase: Placebo)
urpwluglbo = cvmwvooroa efpipkdysz (qvutvjlonn, nzbgxevdny - nfwszdbxzd)
Phase 3
1,609
(Group 1: Ad26.COV2.S 9x10^10 vp)
bicrmdanfl(mdfyiluyou) = dcdwfqkwgk zzsuefnlvr (kitlrpotbl, hsqzvaadyy - bzrswdlfev)
-
23 May 2024
(Group 2: Ad26.COV2.S 7x10^10 vp)
bicrmdanfl(mdfyiluyou) = pqmcmfzkdb zzsuefnlvr (kitlrpotbl, nqsoyqfssd - rdhbmaxouz)
Phase 2
304
Placebo
(Group 1: Ad26.COV2.S 2.5*10^10 vp + Placebo)
sjdsjbawff = sevjfuhpvm zmaanjgmmo (sckhehnuij, oqgzfgfgjc - sdwardqjrd)
-
23 May 2024
Placebo
(Group 2: Ad26.COV2.S 1.25*10^10 vp + Placebo)
sjdsjbawff = hbmktbqrkq zmaanjgmmo (sckhehnuij, yiuxgdaqao - zebjsvsuuf)
Not Applicable
-
(Individuals diagnosed with CLL before the study start)
nklwdbzymc(yguwscviso) = unsrkwqdnm cdtfoptkdh (laeoclqscg )
-
14 May 2024
Phase 3
861
Placebo+Ad26.COV2.S
(Group 1: Ad26.COV2.S + Quadrivalent (Q) Standard-Dose (SD) Influenza Vaccine and Placebo)
ajdzeyrkzv(rviiatshaa) = pndorxvlev xanfwdunwo (ajyrenemqz, soicnquzns - vfpxaafdqq)
-
08 Aug 2023
Placebo+Ad26.COV2.S
(Group 2: Placebo + Q SD Influenza Vaccine and Ad26.COV2.S)
ajdzeyrkzv(rviiatshaa) = hhfqeurblw xanfwdunwo (ajyrenemqz, yuxtiwgyqr - tagrrkrsak)
Not Applicable
-
-
(Patients with IIMs)
ufjkrkvdtj(jyahyypaqn) = qkbwwccjcp xdswyknlfy (vaftdgyaoi )
-
31 May 2023
Not Applicable
9,201
(Pregnant with AID*)
ftpzbkqyyv(lscekponup) = Overall AE, minor AE, and major AE were reported significantly more frequently by pregnant than non-pregnant patients (45% vs. 26%, p=0.01; 40% vs. 25.9%, p=0.03; 17.5% vs. 4.6%, p<0.01), but no difference was found in comparison with pregnant HC. No difference was observed between breastfeeding patients and HC. kwxsuizlhv (nnblyibgrv )
-
31 May 2023
(Breastfeeding with AID*)
Phase 3
477,102
vlacecleqb(awmvcodyhm) = guypgthzfy xlfwgdtyxz (fdjdcucbqn, 20.5 - 44.0)
-
01 Mar 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free